Aisling Capital Management’s Marker Therapeutics MRKR Stock Holding History

Aisling Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$478K	Hold	325,370	–	–	0.1%	13
2026 Q1	$423K	Hold	325,370	–	–	0.09%	12
2025 Q4	$485K	Hold	325,370	–	–	0.1%	12
2025 Q3	$290K	Hold	325,370	–	–	0.06%	13
2025 Q2	$498K	Hold	325,370	–	–	0.14%	12
2025 Q1	$400K	Hold	325,370	–	–	0.14%	12
2024 Q4	$1.01M	Buy	325,370 +11,084	+4%	+$39.3K	0.36%	13
2024 Q3	$886K	Hold	314,286	–	–	0.34%	14
2024 Q2	$1.71M	Hold	314,286	–	–	0.74%	11
2024 Q1	$1.35M	Hold	314,286	–	–	0.46%	12
2023 Q4	$1.73M	Hold	314,286	–	–	0.52%	10
2023 Q3	$1.43M	Hold	314,286	–	–	0.59%	14
2023 Q2	$974K	Hold	314,286	–	–	0.48%	12
2023 Q1	$223K	Hold	314,286	–	–	0.11%	16
2022 Q4	$849K	Hold	314,286	–	–	0.56%	12
2022 Q3	$1.16M	Hold	314,286	–	–	0.77%	13
2022 Q2	$1.04M	Hold	314,286	–	–	0.74%	14
2022 Q1	$1.38M	Hold	314,286	–	–	0.75%	15
2021 Q4	$2.99M	Hold	314,286	–	–	1.05%	16
2021 Q3	$5.31M	Hold	314,286	–	–	1.06%	16
2021 Q2	$8.77M	Hold	314,286	–	–	1.4%	14
2021 Q1	$7.04M	Buy	314,286 +114,286	+57%	+$2.61M	1.27%	11
2020 Q4	$2.9M	Hold	200,000	–	–	0.5%	12
2020 Q3	$3M	Hold	200,000	–	–	0.96%	12
2020 Q2	$4.14M	Hold	200,000	–	–	1.58%	8
2020 Q1	$3.8M	Hold	200,000	–	–	1.66%	9
2019 Q4	$5.76M	Hold	200,000	–	–	2.21%	6
2019 Q3	$10.2M	Hold	200,000	–	–	5.33%	5
2019 Q2	$15.8M	Hold	200,000	–	–	6.77%	3
2019 Q1	$13.2M	Hold	200,000	–	–	10.06%	5
2018 Q4	$11.1M	Buy	+200,000	New	+$14.6M	11.69%	4

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CIA

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aisling Capital Management's MRKR Position: Q2 2026 in Review

Aisling Capital Management held its Marker Therapeutics (MRKR) position steady in Q2 2026 at 325,370 shares worth $478K. The position accounts for 0.1% of the portfolio, ranked #13.

Aisling Capital Management first reported a position in MRKR in Q4 2018 and has held it in 31 quarters since. The position peaked at $15.8M in Q2 2019. 35 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

Aisling Capital Management held 325,370 shares of Marker Therapeutics worth $478K as of Q2 2026.
Aisling Capital Management left its Marker Therapeutics share count unchanged in Q2 2026.
Marker Therapeutics made up 0.1% of Aisling Capital Management's portfolio in Q2 2026, its #13 holding.
Aisling Capital Management first reported a position in Marker Therapeutics in Q4 2018 and has held it in 31 quarters since.
Aisling Capital Management's Marker Therapeutics position peaked at $15.8M in Q2 2019.
35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Aisling Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.